Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mok

Showing results (31-40 of 387) with videos related to

Pageof 39
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2018
Timing of DNA damage responses impacts persistence to fluoroquinolonesWendy W K Mok, Mark P Brynildsen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2020
The More, The Better?Yat-Ming Lau, Tony S K Mok
Lancet (London, England)|June 17, 2014
A REVELation in non-small-cell lung cancer treatment?Tony S K Mok, Herbert H Loong
Journal of Applied Microbiology|July 27, 2024
Agar and agarose used for Staphylococcus aureus biofilm cultivation impact fluoroquinolone toleranceAngela D Power, Wendy W K Mok
The Journal of Thoracic and Cardiovascular Surgery|October 1, 1978
Coexistent bronchogenic carcinoma and active pulmonary tuberculosisC K Mok, P Nandi, G B Ong
Forensic Science International|April 28, 2004
Rapid determination of ketamine in urine by liquid chromatography-tandem mass spectrometry for a high throughput laboratoryJack Y K Cheng, Vincent K K Mok
Thoracic Surgery Clinics|September 24, 2004
Methodology for quality-of-life assessment: a critical appraisalBenny Chung-Ying Zee, Tony S K Mok
Seminars in Oncology|February 26, 2014
Targeting epidermal growth factor receptor in the management of lung cancerTony S K Mok, Kirsty Lee, Linda Leung
Therapeutic Advances in Medical Oncology|July 4, 2012
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancerLinda Leung, Tony S K Mok, Herbert Loong
Thorax|July 1, 1982
Two-dimensional echocardiographic features of Björk-Shiley aortic prosthetic valve dehiscenceR Wang, W T Lee, C K Mok
Pageof 39

Showing results (31-40 of 387) with videos related to

Sort By:
Pageof 39
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2018
Timing of DNA damage responses impacts persistence to fluoroquinolonesWendy W K Mok, Mark P Brynildsen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2020
The More, The Better?Yat-Ming Lau, Tony S K Mok
Lancet (London, England)|June 17, 2014
A REVELation in non-small-cell lung cancer treatment?Tony S K Mok, Herbert H Loong
Journal of Applied Microbiology|July 27, 2024
Agar and agarose used for Staphylococcus aureus biofilm cultivation impact fluoroquinolone toleranceAngela D Power, Wendy W K Mok
The Journal of Thoracic and Cardiovascular Surgery|October 1, 1978
Coexistent bronchogenic carcinoma and active pulmonary tuberculosisC K Mok, P Nandi, G B Ong
Forensic Science International|April 28, 2004
Rapid determination of ketamine in urine by liquid chromatography-tandem mass spectrometry for a high throughput laboratoryJack Y K Cheng, Vincent K K Mok
Thoracic Surgery Clinics|September 24, 2004
Methodology for quality-of-life assessment: a critical appraisalBenny Chung-Ying Zee, Tony S K Mok
Seminars in Oncology|February 26, 2014
Targeting epidermal growth factor receptor in the management of lung cancerTony S K Mok, Kirsty Lee, Linda Leung
Therapeutic Advances in Medical Oncology|July 4, 2012
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancerLinda Leung, Tony S K Mok, Herbert Loong
Thorax|July 1, 1982
Two-dimensional echocardiographic features of Björk-Shiley aortic prosthetic valve dehiscenceR Wang, W T Lee, C K Mok
Pageof 39